 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Massachusetts Supranational TB Reference Laboratory |
| Street 1: | University of Massachusetts Medical School |
| Street 2: | 305 South Street |
| City: | Jamaica Plain |
| Province: | MA |
| Post Code: | 02130 |
| Country: | United States of America |
| Phone: | 508.856.3646 |
| Email: | martin.baker@umassmed.edu |
| Web Site: | http://www.msrl-umassmed.org/ |
|
|
||||||||||||||||||||||||||||
General Information | |
| Organization Type - Primary: | Academic / Research Institution |
| Organization Type - Secondary: | None |
| Is your organization legally registered in your country: | Yes |
| Organization Reach: | International |
| Organization Description: | |
| The Massachusetts Supranational TB Reference Laboratory (MSRL) is a World Health Organization (WHO) appointed SRL. Located at the Massachusetts State Department of Public Health Laboratory, the MSRL is managed and operated by the University of Massachusetts Medical School. As a University-based SRL and long-term laboratory collaborator with Partners In Health (PIH), the MSRL develops and participates in research (basic and operational) and is available to provide technical assistance and training support to developing countries. With an emphasis placed upon the role of quality assurance in laboratory infrastructure development, the MSRL is currently engaged in operational projects in Ecuador, Haiti, and Suriname. MSRL has participated in the development of laboratory infrastructure and provision of interim laboratory support services in the following locations: CAREC (Caribbean Epidemiology Center), Dominican Republic, Ecuador, Haiti, Jamaica Lesotho, Peru, Russia (Tomsk), and Vietnam. The lab regularly organizes and conducts training sessions for both domestic and international participants. |
|
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 6 - 10 |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 0 |
| What is your organization's annual budget (USD) dedicated to TB? | $500,001-$1 MIL |
| How did you hear about the Stop TB Partnership: | Involvement in TB control provision |
| Why do you wish join the Stop TB Partnership: | Technical assistance and advice |
| Are you a member of a Stop TB national partnership: | Peru |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Technical assistance and diagnosis of drug resistant TB in Massachusetts. | |
Geographical Reach | |
| Which country is your headquarters located in: | United States of America |
| Which WHO region is the main focus of your work: | American |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Dominican Republic Ecuador Haiti Jamaica Peru Suriname Trinidad and Tobago United States of America |
Specializations | |
|
Provision of TB products Research and Development TB Healthcare Services Technical Assistance |
Specializations in Countries | |
| Technical Assistance | Dominican Republic |
| Technical Assistance | Ecuador |
| Technical Assistance | Haiti |
| Technical Assistance | Jamaica |
| Technical Assistance | Peru |
| Technical Assistance | Suriname |
| Technical Assistance | Trinidad and Tobago |
| Technical Assistance | United States of America |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: Direct provision of diagnostics to high burden locations with insufficient capacity. Laboratory Strengthening: Development of laboratory capacity in developing and middle income countries within the America's Region. New Diagnostics: Evaluation and validation of new rapid molecular technologies. Operational Research: Development and implementation of surveillance for drug resistance in multiple countries, including Haiti and Ecuador. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | April 24, 2009 |
| Last updated: | May 9, 2012 |